They expect that the first countries to emerge from the pandemic
will have had some combination of high rates of vaccination and
natural immunity among people who were infected with the coronavirus,
such as the United States, the UK, Portugal and India. But they warn
that SARS-CoV-2 remains an unpredictable virus that is mutating as
it spreads through unvaccinated populations.
None would completely rule out what some called a "doomsday
scenario," in which the virus mutates to the point that it evades
hard-won immunity. Yet they expressed increasing confidence that
many countries will have put the worst of the pandemic behind them
in the coming year.
"We think between now and the end of 2022, this is the point where
we get control over this virus ... where we can significantly reduce
severe disease and death," Maria Van Kerkhove, an epidemiologist
leading the World Health Organization's (WHO) COVID-19 response,
told Reuters.
The agency's view is based on work with disease experts who are
mapping out the probable course of the pandemic over the next 18
months. By the end of 2022, the WHO aims for 70% of the world's
population to be vaccinated.
"If we reach that target, we will be in a very, very different
situation epidemiologically," Van Kerkhove said.
In the meantime, she worries about countries lifting COVID
precautions prematurely. "It's amazing to me to be seeing, you know,
people out on the streets, as if everything is over."
COVID-19 cases and deaths have been declining since August in nearly
all regions of the world, according to the WHO's report on Oct. 26.
Europe has been an exception, with Delta wreaking new havoc in
countries with low vaccination coverage such as Russia and Romania,
as well as places that have lifted mask-wearing requirements. The
variant has also contributed to rising infections in countries such
as Singapore and China, which have high rates of vaccination but
little natural immunity due to much stricter lockdown measures.
![](http://archives.lincolndailynews.com/2021/Nov/03/images/ads/current/LPL_small%201.gif)
“The transition is going to be different in each place because it's
going to be driven by the amount of immunity in the population from
natural infection and of course, vaccine distribution, which is
variable ... from county by county to country by country,” said Marc
Lipsitch, an epidemiologist at Harvard T.H. Chan School of Public
Health.
Several experts said they expect the U.S. Delta wave will wrap up
this month, and represent the last major COVID-19 surge.
"We're transitioning from the pandemic phase to the more endemic
phase of this virus, where this virus just becomes a persistent
menace here in the United States," former Food and Drug
Administration Commissioner Scott Gottlieb said.
Chris Murray, a leading disease forecaster at the University of
Washington, likewise sees the U.S. Delta surge ending in November.
"We'll go into a very modest winter increase" in COVID-19 cases, he
said. "If there's no major new variants, then COVID starts to really
wind down in April."
Even where cases are spiking as countries drop pandemic
restrictions, as in the UK, vaccines appear to be keeping people out
of the hospital.
[to top of second column] |
![](http://archives.lincolndailynews.com/2021/Nov/03/images/ads/current/topflight_sda_SFARM_2020.png)
Epidemiologist Neil Ferguson of Imperial College London said that
for the UK, the "bulk of the pandemic as an emergency is behind us."
'A GRADUAL EVOLUTION'
COVID-19 is still expected to remain a major contributor to illness
and death for years to come, much like other endemic illnesses such
as malaria.
"Endemic does not mean benign," Van Kerkhove said.
Some experts say the virus will eventually behave more like measles,
which still causes outbreaks in populations where vaccination
coverage is low.
![](http://archives.lincolndailynews.com/2021/Nov/03/images/ads/current/safety-tip-daily-3.png)
Others see COVID-19 becoming more a seasonal respiratory disease
such as influenza. Or, the virus could become less of a killer,
affecting mostly children, but that could take decades, some said.
Imperial College's Ferguson expects above-average deaths in the UK
from respiratory disease due to COVID-19 for the next two-to-five
years, but said it is unlikely to overwhelm health systems or
require social distancing be reimposed.
"It's going to be a gradual evolution," Ferguson said. "We're going
to be dealing with this as a more persistent virus."
Trevor Bedford, a computational virologist at Fred Hutchinson Cancer
Center who has been tracking the evolution of SARS-CoV-2, sees a
milder winter wave in the United States followed by a transition to
endemic disease in 2022-2023. He is projecting 50,000 to 100,000
U.S. COVID-19 deaths a year, on top of an estimated 30,000 annual
deaths from flu.
The virus will likely continue to mutate, requiring annual booster
shots tailored to the latest circulating variants, Bedford said.
If a seasonal COVID scenario plays out, in which the virus
circulates in tandem with the flu, both Gottlieb and Murray expect
it to have a significant impact on healthcare systems.
"It'll be an issue for hospital planners, like how do you deal with
the COVID and flu surges in winter," Murray said. "But the era of
... massive public intervention in people's lives through mandates,
that part I believe will be done after this winter surge."
Richard Hatchett, chief executive of the Coalition for Epidemic
Preparedness Innovations, said with some countries well protected by
vaccines while others have virtually none, the world remains
vulnerable.
![](http://archives.lincolndailynews.com/2021/Nov/03/images/ads/current/charrons_bch041713.png)
"What keeps me up at night about COVID is the concern that we could
have a variant emerge that evades our vaccines and evades immunity
from prior infection,” Hatchett said. “That would be like a new
COVID pandemic emerging even while we're still in the old one."
(Reporting by Julie Steenhuysen; Editing by Michele Gershberg and
Bill Berkrot)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |